Preview Mode Links will not work in preview mode

This Week in Cardiology

Oct 7, 2022

Post-PCI antiplatelet therapy, palliative care in patients with HF, Watchman information on hospital websites, and HCM in athletes are the topics John Mandrola, MD, covers in this week’s podcast.

This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit:

I. Post-Stent Antiplatelet Therapy

SMART-CHOICE 3-Year Results Support Dropping Aspirin After PCI

  • Long-term Effects of P2Y12 Inhibitor Monotherapy After Percutaneous Coronary Intervention
  • The Smart(est) Choice for Dual Antiplatelet Therapy is a Patient-Directed One
  • Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention

II. Palliative Care in HF

Home-Based Palliative Care Improves Heart Failure Outcomes

  • Regional collaborative home-based palliative care and health care outcomes among adults with heart failure

III. Watchman Info on Hospital Websites

Concern Over US Hospital Patient Information on LAA Closure

  • Analysis of Patient-Focused Information About Left Atrial Appendage Occlusion on US Hospital Web Pages

IV. HCM and Exercise in Athletes

Athletes With Mild HCM Can Likely Continue Competitive Sports

  • Impact of Exercise on Outcomes and Phenotypic Expression in Athletes With Nonobstructive Hypertrophic Cardiomyopathy
  • A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD)

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

Questions or feedback, please contact